These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 4004983)

  • 1. The effects on lipids, blood viscosity and platelet aggregation of combined use of niceritrol (Perycit) and a low dose of acetylsalicylic acid.
    Hamazaki T; Hasunuma K; Kobayashi S; Shishido H; Yano S
    Atherosclerosis; 1985 Apr; 55(1):107-13. PubMed ID: 4004983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-platelet effect of niceritrol in patients with arteriosclerosis and the relationship of the lipid-lowering effect to the anti-platelet effect.
    Nagakawa Y; Orimo H; Harasawa M
    Thromb Res; 1985 Nov; 40(4):543-53. PubMed ID: 4082125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Vessby B; Lithell H; Gustafsson IB; Borberg J
    Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing.
    Nozaki S; Kihara S; Kubo M; Kameda K; Matsuzawa Y; Tarui S
    Int J Clin Pharmacol Ther Toxicol; 1987 Dec; 25(12):643-7. PubMed ID: 3481359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antilipemic effectiveness of pentaerythritol tetranicotinate on hyperlipidemic patients with or without diabetes mellitus--a double-blind, randomized and two-period change-over experiment.
    Ho LT; Chern JC; Hsu SC; Chen RL; Kwok CF; Wu MS; Chen JJ; Jap TS
    Proc Natl Sci Counc Repub China B; 1985 Jan; 9(1):20-9. PubMed ID: 3916369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
    Oida K; Nakai T; Tamai T; Kutsumi Y; Kobayashi T; Hayashi T; Yamada S; Takeda R
    Artery; 1982; 10(4):266-85. PubMed ID: 7181672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia.
    Matsunaga A; Handa K; Mori T; Moriyama K; Hidaka K; Yuki M; Sasaki J; Arakawa K
    Atherosclerosis; 1992 Jun; 94(2-3):241-8. PubMed ID: 1385959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
    Gajdos M; Fedelesova V; Mongiellova V; Cibulova L; Huttova D; Polak F; Krivosikova Z
    Bratisl Lek Listy; 1999 Aug; 100(8):449-53. PubMed ID: 10645034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response effect of single and combined clofibrate (Atromidin) and niceritrol (Perycit) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia.
    Olsson AG; Orö L; Rössner S
    Atherosclerosis; 1975; 22(1):91-101. PubMed ID: 1098680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia.
    Kibata M; Ishida M; Asano K; Uehara H; Saito K; Fuchimoto T; Ugaki K; Murakami H; Matoba K; Kotakemori Y; Shirai K; Yoshioka H; Nanba M; Yasuda M; Ishizaki M; Kitagawa N; Ikejiri K; Inohara R; Lee BJ; Saino S; Sakado J; Matuzaka H; Numata K; Mandai M; Miyake K; Nakamura K
    Atherosclerosis; 1980 Nov; 37(3):333-42. PubMed ID: 7458980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and laboratory responses to niceritrol in the treatment of hypercholesterolaemia.
    Curtis LD; Reckless JP; Winder AF; Betteridge DJ
    Postgrad Med J; 1988 Sep; 64(755):672-5. PubMed ID: 3075043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemorheological background of acetylsalicylic acid resistance.
    Feher G; Koltai K; Kesmarky G; Toth K
    Clin Hemorheol Microcirc; 2008; 38(3):143-52. PubMed ID: 18239256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender differences in hemorheological parameters and in in vitro platelet aggregation in acetylsalicylic acid and clopidogrel treated vascular patients.
    Koltai K; Papp J; Kenyeres P; Feher G; Tibold A; Alexy T; Marton Z; Kesmarky G; Toth K
    Biorheology; 2014; 51(2-3):197-206. PubMed ID: 24898335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of combination therapy with niceritrol and pravastatin on hyperlipidaemia.
    Kinoshita M; Mikuni Y; Kudo M; Mori M; Horie E; Teramoto T; Matsushima T
    J Int Med Res; 2002; 30(3):271-81. PubMed ID: 12166344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of nicotinic acid, niceritrol and beta-pyridylcarbinol on experimental hyperlipidemia and atherosclerosis in mini-pigs.
    Lundholm L; Jacobsson L; Brattsand R; Magnusson O
    Atherosclerosis; 1978 Feb; 29(2):217-39. PubMed ID: 646851
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of different dose regimens of niceritrol of serum lipid concentrations in man.
    Rössner S; Olsson AG; Orö L
    Acta Med Scand; 1976; 200(4):269-71. PubMed ID: 983794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of aspirin upon the flushing reaction induced by niceritrol.
    Jay RH; Dickson AC; Betteridge DJ
    Br J Clin Pharmacol; 1990 Jan; 29(1):120-2. PubMed ID: 2297456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables.
    Feher G; Koltai K; Papp E; Alkonyi B; Solyom A; Kenyeres P; Kesmarky G; Czopf L; Toth K
    Drugs Aging; 2006; 23(7):559-67. PubMed ID: 16930084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent effect of niceritrol on plasma lipoprotein-a.
    Teramoto T; Yamada N; Shimano H; Oka Y; Itakura H; Saito Y; Morisaki N; Shirai K; Ishikawa T; Tada N; Ito H; Yamanouchi T; Matsushima T; Kawakami M; Murase T; Okubo M; Totsuka Y; Kikuchi M
    Scand J Clin Lab Invest; 1996 Jul; 56(4):359-65. PubMed ID: 8837243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.